A. Flechon

A. Masson-Lecomte, Y. Allory, P. Camparo, 2022, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Brain metastases from germ cell tumor: time to reconsider radiotherapy?

C. Chevreau, J. Khalifa, A. Flechon, 2020, Critical reviews in oncology/hematology.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma

S. Culine, G. Gravis, N. Houédé, 2016, BJU international.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

A rare case of advanced testicular seminoma in a 78-year-old man managed successfully with carboplatin based chemotherapy: a case report

J. Droz, O. Masbah, A. Fléchon, 2008, Cases journal.

Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data.

J. Lortet-Tieulent, D. Forman, F. Bray, 2014, European journal of cancer.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

P. Hegde, A. Ravaud, T. Powles, 2018, The Lancet.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

J. Blay, V. Grégoire, B. Fervers, 2021, ESMO open.

Could Aberrant Migration Explain Metachronous Germ Cell Tumors?

C. Faure-Conter, J. Jacquemus, T. Fenouil, 2020, Cancer investigation.

Report of a young man with three successive curable cancers.

X. Pivot, J. Droz, M. Pavić, 2008, European journal of internal medicine.

Long‐term oncological outcome after post‐chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour

J. Droz, M. Rivoire, A. Fléchon, 2010, BJU international.

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

S. Culine, A. Horwich, P. Albers, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review

N. Houédé, F. Cornelis, P. Richaud, 2014, Prostate Cancer and Prostatic Disease.

Amplification and over‐expression of OZF, a gene encoding a zinc finger protein, in human pancreatic carcinomas

S. Hanash, B. Dutrillaux, B. Terris, 1999, International journal of cancer.

Chemotherapy in advanced bladder cancer: current status and future

A. Fléchon, N. Ismaili, M. Amzerin, 2011, Journal of hematology & oncology.

Abiraterone and increased survival in metastatic prostate cancer.

Arturo Molina, Tina Cheng, Fred Saad, 2011, The New England journal of medicine.

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

N. Agarwal, G. Kramer, M. Carducci, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

F. Saad, C. Redfern, N. Clarke, 2018, The Lancet. Oncology.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

A. Ravaud, T. Powles, J. Carles, 2021, Nature Medicine.

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.

M. Galsky, P. Sharma, A. Patnaik, 2020, Cancer cell.

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

J. Carles, B. Tombal, F. Calabrò, 2022, The Lancet.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

A. Ravaud, S. Culine, G. Deplanque, 2015, The Lancet. Oncology.

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

C. Parker, K. Miller, C. Sternberg, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.

C. Bokemeyer, L. Kanz, P. Biron, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study

C. Bokemeyer, K. Oechsle, A. Necchi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma.

A. Fléchon, S. Négrier, H. Boyle, 2022, Clinical genitourinary cancer.

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

N. Rioux-Leclercq, A. Ravaud, B. Escudier, 2020, European journal of cancer.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

S. Culine, Y. Allory, G. Gravis, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.

S. Culine, Y. Allory, W. Hilgers, 2021, Clinical genitourinary cancer.

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Patho

S. Culine, Y. Allory, G. Gravis, 2020, European urology.

Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol

D. Orbach, E. Thébaud, F. Dijoud, 2022, Pediatric blood & cancer.

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).

N. Rioux-Leclercq, F. Goldwasser, B. Escudier, 2021, European journal of cancer.

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.

S. Richard, G. De Velasco, J. Scoazec, 2021, European journal of cancer.

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

S. Fosså, A. Horwich, R. Huddart, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

S. Culine, G. Deplanque, J. Droz, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer ( mCRPC ) with or without neuroendocrine differentiation : results of the French GenitoUrinary Tumor Group ( GETUG ) P 01 trial

S. Culine, G. Deplanque, J. Droz, 2011 .

Outcome of recurrent and metastatic small cell carcinoma of the bladder

J. Droz, A. Fléchon, P. Heudel, 2009, BMC Urology.

Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis.

J. Blay, J. Droz, A. Fléchon, 2009, Bulletin du cancer.

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

D. Spaeth, S. Oudard, P. Barthélémy, 2018, European urology oncology.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

A. Ravaud, S. Culine, G. Deplanque, 2012, European journal of cancer.

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.

A. Italiano, S. Oudard, G. Gravis, 2009, European urology.

Results of the FLAC European Database of Metastatic Castration‐Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents

E. Esteban, J. Bellmunt, S. Oudard, 2018, Clinical genitourinary cancer.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

S. Oudard, G. Gravis, X. Rébillard, 2017, Cancer treatment reviews.

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up.

A. Ravaud, S. Culine, G. Le Teuff, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

802PPatient preference between Cabazitaxel and Docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): Results from the CABADOC randomized trial

S. Culine, G. Gravis, P. Barthélémy, 2017 .

Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

S. Oudard, G. Gravis, P. Beuzeboc, 2014 .

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Thierry Gil, Camilla Thellenberg Karlsson, I. Tannock, 2013, The Lancet. Oncology.

Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).

S. Culine, G. Gravis, F. Joly, 2019, Journal of Clinical Oncology.

Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.

D. Spaeth, S. Oudard, S. Chowdhury, 2019, Journal of Clinical Oncology.

LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1

B. Tombal, F. Calabrò, S. Foulon, 2021, Annals of Oncology.

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

B. Tombal, F. Calabrò, S. Foulon, 2021 .

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

D. Spaeth, S. Oudard, P. Barthélémy, 2019, European journal of cancer.

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?

B. Tran, M. Hofman, K. Fizazi, 2021, Therapeutic advances in medical oncology.

Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Andrew Kramar, Caroline Bascoul-Mollevi, Christophe Massard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

J. Bono, M. Cornfeld, G. Hudes, 2012, European journal of cancer.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

J. Burke, J. Gschwend, C. Sternberg, 2015, The Lancet. Oncology.

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

M. Galsky, P. Sharma, A. Patnaik, 2019, Journal of Clinical Oncology.

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.

A. Horwich, J. Gampe, K. Oechsle, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

S. Culine, G. Gravis, P. Barthélémy, 2022, European urology.

Management of post-chemotherapy residual masses in advanced seminoma.

P. Biron, J. Droz, A. Fléchon, 2002, The Journal of urology.

[Testicular germ cell tumours and early exposures to pesticides: The TESTEPERA pilot study].

Helen Boyle, Elodie Faure, Joachim Schüz, 2014, Bulletin du cancer.

Domestic use of pesticides during early periods of development and risk of testicular germ cell tumors in adulthood: a French nationwide case-control study

B. Fervers, F. Eustache, B. Charbotel, 2021, Environmental Health.

Studying the impact of early life exposures to pesticides on the risk of testicular germ cell tumors during adulthood (TESTIS project): study protocol

B. Fervers, B. Charbotel, J. Schüz, 2014, BMC Cancer.

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area

C. Théodore, J. Droz, A. Laplanche, 2005, British Journal of Cancer.

Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeurs du pénis

P. Camparo, P. Sèbe, T. Murez, 2018, Progrès en Urologie.

Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.

T. Powles, C. Bascoul-Mollevi, L. Einhorn, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.

G. Gravis, S. Ladoire, D. Pouessel, 2022, European journal of cancer.

Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial

T. Powles, D. Petrylak, Chia‐Chi Lin, 2020 .

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.

S. Culine, Y. Allory, G. Gravis, 2021, Clinical genitourinary cancer.

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

T. Powles, A. Alva, S. Oudard, 2021, The Lancet. Oncology.

LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2020 .

TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.

N. Agarwal, C. Sternberg, D. Petrylak, 2022, Journal of Clinical Oncology.

700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2021, Annals of Oncology.

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA).

M. Maio, P. Barthélémy, A. Necchi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.

S. Chevret, J. Grob, T. Jouary, 2022, European journal of cancer.

Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.

G. De Velasco, B. Escudier, P. Barthélémy, 2022, European journal of cancer.

Sorafenib and sunitinib for elderly patients with renal cell carcinoma.

J. Droz, A. Fléchon, C. Terret, 2013, Journal of geriatric oncology.

[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].

A. Fléchon, S. Négrier, H. Boyle, 2010, Bulletin du cancer.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

J. Blay, S. Boyault, S. Lantuejoul, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

French AFU Cancer Committee Guidelines Update 2022-2024: Adrenal tumor - Assessment of an adrenal incidetaloma and oncological management.

P. Camparo, T. Murez, A. Fléchon, 2022, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Management of advanced germ-cell tumors of the testis

J. Droz, M. Rivoire, A. Flechon, 2008, Nature Clinical Practice Urology.

[French ccAFU guidelines - update 2020-2022: malignancy assessment of an adrenal incidentaloma].

P. Camparo, T. Murez, A. Méjean, 2020, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Malignant melanoma presenting as an ampullary tumour

T. Ponchon, J. Saurin, J. Scoazec, 2002, Histopathology.

Treatment of Relapse

J. Droz, A. Fléchon, A. Flechon, 2011 .

Intensive and timely chemotherapy, the key of success in testicular cancer.

S. Culine, J. Droz, A. Fléchon, 2001, Critical reviews in oncology/hematology.

Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.

S. Oudard, G. Gravis, P. Beuzeboc, 2013 .

Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

S. Oudard, G. Gravis, K. Fizazi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[CCAFU Recommendations 2013: Penile cancer].

S. Culine, P. Camparo, P. Sèbe, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

S. Culine, C. Logothetis, G. Le Teuff, 2017, European journal of cancer.

[The role of chemotherapy in the management of bladder cancer].

J. Droz, A. Fléchon, H. Errihani, 2011, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

B. Bui, P. Biron, J. Bay, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Sarcoid-Like Granulomatosis and Testicular Germ Cell Tumor: The ‘Great Imitator’

J. Droz, G. Chatté, H. Errihani, 2011, Oncology.

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

S. Culine, E. Gallardo, J. Droz, 2009, Marine drugs.

High‐dose chemotherapy with hematopoietic stem‐cell support in germ‐cell tumor patient treatment: The French experience

P. Biron, J. Droz, A. Flechon, 1999, International journal of cancer.

Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience

J. Droz, A. Fléchon, P. Heudel, 2009, BMC urology.

[CCAFU's contribution to the French National Cancer Institute's reference frame: Adrenal malignant tumors].

P. Camparo, P. Sèbe, L. Brunaud, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeur de la surrénale

P. Camparo, P. Sèbe, T. Murez, 2018, Progrès en Urologie.

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

S. Culine, J. Bellmunt, W. Su, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[French ccAFU guidelines - Update 2018-2020: Retroperitoneal sarcoma].

P. Camparo, P. Sèbe, T. Murez, 2018, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Chemotherapy practices and perspectives in invasive bladder cancer

J. Droz, A. Fléchon, A. Flechon, 2006, Expert review of anticancer therapy.

tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

A. Horwich, J. Gampe, K. Oechsle, 2011 .

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

S. Oudard, G. Gravis, K. Fizazi, 2014, European journal of cancer.

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy.

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2020, European urology focus.

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)

C. Bokemeyer, T. Hermanns, C. Fankhauser, 2019, Cancer medicine.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

S. Oudard, G. Gravis, N. Houédé, 2015, BMC Cancer.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

S. Culine, Y. Allory, S. Oudard, 2019, Clinical genitourinary cancer.

Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients.

J. Droz, A. Fléchon, Luis Cereceda, 2003, Clinical prostate cancer.

Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.

S. Culine, G. Gravis, F. Joly, 2021, European urology.

Clinical Management of Elderly Patients’ Metastatic Prostate Cancer: Other Treatments and Supportive Care

H. Boyle, A. Flechon, 2013 .

Management of Brain Metastases from Germ Cell Tumors: A Single Center Experience

J. Droz, A. Fléchon, E. Jouanneau, 2013, Oncology.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

D. Spaeth, S. Oudard, M. Krainer, 2018, European journal of cancer.

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

F. Saad, V. Matveev, S. Hotte, 2017, The Lancet. Oncology.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

S. Culine, C. Logothetis, G. Gravis, 2014, The Lancet. Oncology.

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

S. Culine, Y. Allory, G. Gravis, 2023, Cancers.

Pattern of relapse after first line treatment of advanced stage germ-cell tumors.

S. Culine, C. Théodore, J. Droz, 2005, European urology.

Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors.

P. Biron, J. Droz, M. Rivoire, 2001, The Journal of urology.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

S. Culine, G. Gravis, N. Houédé, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Retroperitoneal vascular surgery for the treatment of giant growing teratoma syndrome.

J. Droz, A. Gandini, I. Aleksic, 2012, Urology.

Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.

S. Culine, B. Besse, C. Théodore, 2009, The Journal of thoracic and cardiovascular surgery.

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.

S. Fosså, A. Dunant, S. Tjulandin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Tailored Treatment for Bladder Cancer in Older Patients

R. Audisio, J. Droz, C. Terret, 2013 .

Management of elderly patients with advanced infiltrating and metastatic bladder cancer: an oncogeriatric approach

J. Droz, C. Terret, H. Boyle, 2011 .

Primitive Seminoma of the Thyroid Gland: A Novel Situation, an Exceptional Primitive Location

G. Buiret, R. Barnoud, A. Ambrun, 2014 .

789PPROGNOSTIC FACTORS FOR SURVIVAL AND SEQUENCING OF LIFE-EXTENDING THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) IN POST-DOCETAXEL (D) SETTING.

E. Esteban, J. Bellmunt, S. Oudard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study.

S. Culine, F. Joly, N. Houédé, 2009, Clinical genitourinary cancer.

Gemcitabine in bladder cancer

A. Fléchon, F. Karak, A. Flechon, 2007, Expert opinion on pharmacotherapy.

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma

T. Powles, G. Sonpavde, C. Sternberg, 2022, European Journal of Cancer.

[CCAFU french national guidelines 2016-2018 on retroperitoneal sarcoma].

P. Camparo, P. Sèbe, T. Murez, 2016, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study

V. Brouste, O. Chapet, P. Richaud, 2017, PloS one.

Localized testicular germ cell tumor surveillance: A Delphi consensus study.

S. Culine, F. Joly, K. Fizazi, 2020 .

Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.

G. Gravis, F. Joly, P. Barthélémy, 2021, European journal of cancer.

Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

S. Culine, D. Drubay, G. Deplanque, 2023, Clinical Genitourinary Cancer.

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

M. Burotto, A. Armstrong, L. Lacombe, 2022, Journal for ImmunoTherapy of Cancer.

Prostate cancer: management of advanced disease.

J. Droz, A. Fléchon, C. Terret, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.

L. Einhorn, A. Necchi, A. Kramar, 2010 .

614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects

P. Barthélémy, K. Fizazi, A. Thiery-Vuillemin, 2020 .

Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).

Y. Allory, S. Oudard, G. Gravis, 2023, European journal of cancer.

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Y. Allory, S. Oudard, G. Gravis, 2020 .

Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.

S. Chevret, B. Escudier, S. Oudard, 2020 .

Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine.

N. Mottet, O. Riou, D. Azria, 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

S. Culine, A. Paci, J. Bay, 2021, Cancer medicine.

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

S. Broutin, A. Paci, J. Bay, 2017, Clinical Cancer Research.

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

T. Powles, H. Nishiyama, H. Harputluoglu, 2019, The Lancet. Oncology.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring

J. Delahousse, J. Bay, G. Gravis, 2019, Therapeutic drug monitoring.

Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicentric prospective GETUG trial.

S. Culine, J. Bay, G. Gravis, 2017 .

Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).

S. Culine, M. Santis, J. Bellmunt, 2014 .

Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.

B. Ribba, J. Droz, A. Fléchon, 2010, Urology.

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients

S. Culine, V. Brouste, P. Pourquier, 2015, Journal of Negative Results in BioMedicine.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

J. Shamash, P. Hutton, O. Ståhl, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

S. Oudard, P. Barthélémy, A. Thiery-Vuillemin, 2022, Journal of oncology.

Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.

S. Culine, S. Bastuji‐Garin, E. Paillaud, 2017, Urologic oncology.

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

T. Powles, C. Sternberg, D. Petrylak, 2022, British journal of clinical pharmacology.

[French ccAFU guidelines - Update 2018-2020: Testicular germ cell tumors].

P. Camparo, P. Sèbe, T. Murez, 2018, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[Surgery of residual masses after chemotherapy in patients with testicular cancer].

N. Berger, M. Rivoire, A. Flechon, 2007, La Revue du praticien.

[Prostate cancer in elderly subjects: how diagnosis should be made, why and how geriatric assessment should be implemented].

N. Mottet, A. Ruffion, R. Bensadoun, 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

French AFU Cancer Committee Guidelines - Update 2022-2024: penile cancer.

P. Camparo, T. Murez, R. Mathieu, 2022, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma

T. Powles, H. Nishiyama, C. Sternberg, 2017 .

French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease.

P. Camparo, E. Barret, A. Ruffion, 2022, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[CCAFU Recommendations 2013: Testicular germ cell cancer].

S. Culine, P. Camparo, P. Sèbe, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Rechallenge of nivolumab in metastatic renal cell carcinoma, an ambispective multicenter study (RENIVO).

S. Oudard, P. Barthélémy, A. Thiery-Vuillemin, 2021 .

[French ccAFU guidelines - update 2020-2022: penile cancer].

P. Camparo, T. Murez, A. Fléchon, 2020, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group

Y. Neuzillet, M. Laramas, A. Fléchon, 2023, Frontiers in Oncology.

F. Saad, C. Redfern, N. Clarke, 2019, Journal of Clinical Oncology.

Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC).

J. Droz, S. Chabaud, H. Boyle, 2013 .

[CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].

P. Camparo, P. Sèbe, T. Murez, 2016, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

S. Culine, C. Logothetis, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.

C. Théodore, P. Kerbrat, K. Fizazi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of clinical Stage I nonseminomatous germ-cell testis tumors

J. Droz, A. Fléchon, A. Flechon, 2003, Expert review of anticancer therapy.

French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance.

P. Camparo, E. Barret, A. Ruffion, 2022, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathol

S. Culine, Y. Allory, G. Gravis, 2020 .

New Drugs in the Treatment of Germ Cell Tumours

J. Blay, J. Droz, A. Flechon, 2008 .

Lung toxicity in a patient treated with sunitinib

M. Rivoire, A. Fléchon, G. Chatté, 2012, European Respiratory Journal.

Small cell cancer of the bladder: The Leon-Berard cancer centre experience

J. Droz, A. Fléchon, P. Heudel, 2008, Indian journal of urology : IJU : journal of the Urological Society of India.

[Securing patients pathways treated by oral antitumoral: Guidelines for better organization of departments and management of incoming calls].

F. Joly, C. Bertrand, É. Lecarpentier, 2019, Bulletin du cancer.

Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).

B. Escudier, S. Oudard, G. Gravis, 2020 .

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

R. Jones, F. Saad, C. Redfern, 2018 .

Post‐chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study

L. Salomon, P. Sèbe, G. Pignot, 2016, Journal of surgical oncology.

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.

J. Blay, S. Boyault, S. Lantuejoul, 2019 .

Initial management of testicular cancer: practice survey among urologists and pathologists.

S. Culine, P. Camparo, P. Sèbe, 2014, Clinical genitourinary cancer.

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma

A. Giraudet, A. Fléchon, J. Badel, 2023, Pharmaceuticals.

[CCAFU's contribution to the French National Cancer Institute's reference frame: Retroperitoneal sarcomas].

P. Camparo, P. Sèbe, T. Murez, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.

J. Carles, B. Tombal, F. Calabrò, 2023, Journal of Clinical Oncology.

1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial

J. McCaffrey, F. Calabrò, A. Thiery-Vuillemin, 2022, Annals of Oncology.

1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.

T. Powles, A. Alva, S. Oudard, 2021 .

[CCAFU french national guidelines 2016-2018 on penile cancer].

P. Camparo, P. Sèbe, T. Murez, 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

Chemotherapy in advanced bladder cancer: current status and future

N. Ismaili, M. Amzerin, A. Flechon, 2011 .

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE).

B. Tombal, V. Matveev, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

J. Hajdenberg, R. Motzer, D. Feldman, 2013, Investigational New Drugs.

Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeurs germinales du testicule

P. Camparo, P. Sèbe, T. Murez, 2018, Progrès en Urologie.

Recommandations françaises du Comité de cancérologie de l’AFU - actualisation 2020-2022 : bilan de malignité d’un incidentalome surrénalien

P. Camparo, T. Murez, A. Méjean, 2020, Progrès en Urologie.

Gemcitabine in bladder cancer

F. Karak, A. Flechon, 2007, Expert opinion on pharmacotherapy.

Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.

A. Italiano, S. Oudard, G. Gravis, 2009, European urology.

[Treatment of testicular cancer].

S. Culine, J. Droz, K. Fizazi, 2013, Bulletin du cancer.

Study of the conformity of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) to standard recommendations in patients with testicular (T) and primary retroperitoneal (PR) non-seminomatous germ-cell tumor (NSGCT): impact on outcome

J. Droz, M. Rivoire, E. Tavernier, 2004 .

[Testicular germ cell tumours and early exposures to pesticides: The TESTEPERA pilot study].

B. Fervers, B. Charbotel, J. Schüz, 2014, Bulletin du cancer.

2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.

A. Horwich, J. Gampe, K. Oechsle, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.

S. Culine, B. Besse, C. Théodore, 2009, The Journal of thoracic and cardiovascular surgery.